In 2026, the FDA cleared PrecivityAD2 for adults 40 and older who have symptoms of cognitive impairment. The blood test can estimate whether brain amyloid plaques are likely, but it cannot diagnose Alzheimer's on its own and is not a screening test.
"Younger-onset" Alzheimer's means symptoms begin before age 65. C2N Diagnostics describes PrecivityAD2 as the first cleared Alzheimer's blood test to include symptomatic adults as young as 40. However, the cleared version was not yet available as of the company's August update.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who may be considered for PrecivityAD2?
- What does the blood result mean?
- How strong is the real-world evidence?
- Why does a full evaluation still come first?
- What should adults with new symptoms do now?
Who may be considered for PrecivityAD2?
The FDA device database lists precivityad2 as a Class II device found "substantially equivalent." This supports calling it FDA-cleared rather than describing it as a stand-alone diagnostic approval. The intended population is adults 40 or older with cognitive-impairment symptoms who are already being evaluated for Alzheimer's or another cause of decline. According to C2N's clearance announcement, a clinician experienced in cognitive assessment must interpret the result alongside other patient information.
The test is not intended for people without symptoms who want to learn their future Alzheimer's risk. Age alone also does not establish younger-onset Alzheimer's: the National Institute on Aging says fewer than 10% of people with Alzheimer's develop symptoms before 65. Nor does younger onset necessarily mean an inherited genetic form. The agency attributes only 10% to 15% of younger-onset cases to variants in APP, PSEN1, or PSEN2.
What does the blood result mean?
PrecivityAD2 measures ratios of amyloid-beta and tau peptides in a blood sample. It combines those measurements into an Amyloid Probability Score 2, which estimates the likelihood that amyloid plaques are present in the brain. That result addresses amyloid pathology, not the complete cause of someone's symptoms.
A positive result does not independently establish an Alzheimer's diagnosis, while a negative result does not identify another explanation. In C2N's manufacturer-reported validation study of 1,142 symptomatic people, 97.6% of positive results were positive against amyloid PET or spinal-fluid biomarkers. Among negative results, 93.1% were negative against those reference methods. Those predictive values describe the study population; they are not guarantees for an individual patient or every clinical setting.
How strong is the real-world evidence?
Interim Swedish data offer evidence that the test may improve diagnostic decisions outside a validation study. Among 1,310 people with mild cognitive impairment or dementia, diagnostic accuracy increased from 65% to 93% in primary care after clinicians received PrecivityAD2 results. Accuracy among specialists increased from 74% to 89%, according to the Alzheimer's Association's AAIC report.
These were interim findings reported at a conference, so they should be treated as preliminary rather than definitive evidence. The findings also concern a broad group with cognitive impairment or dementia. They should not be read as separate proof of performance specifically among adults ages 40 to 64.
Why does a full evaluation still come first?
New memory or thinking problems have several possible explanations. The National Institute on Aging's diagnostic guidance says clinicians consider medical history and cognitive function and may investigate medication effects, depression, sleep problems, infection, stroke, or another dementia. A clinical evaluation helps determine whether biomarker testing is useful and how the result fits the person's symptoms.
It also reduces the risk of treating an amyloid result as the answer when another condition may be contributing. For the same reason, patients should not order or interpret the test as a self-diagnosis. Its intended use requires clinical assessment and consideration of other patient information.
What should adults with new symptoms do now?
As of C2N's August 2026 update, the FDA-cleared version was expected later in 2026 but was not yet available. The company's existing CLIA laboratory-developed version was intended for symptomatic patients age 50 and older, so the two versions should not be treated as interchangeable. Practical next steps include:.
- Schedule an evaluation rather than waiting for symptoms to become severe.
- Write down when the changes began and specific examples of how they affect daily tasks.
- Bring a current medication list and mention changes in sleep or mood.
- Ask whether an amyloid biomarker test would clarify the evaluation.
- Confirm which PrecivityAD2 version is available and what age indication applies before arranging the blood draw.
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Adults With New Memory Symptoms Should Know About the News
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Adults With New Memory Symptoms Should Know About the News
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Adults With New Memory Symptoms Should Know About the News
